Moleculin Biotech Announces Preclinical Data on Annamycin in Pancreatic Cancer

What Happened
Moleculin Biotech, Inc. (MBRX) filed an 8‑K on September 25, 2026 (Regulation FD disclosure) announcing a press release presenting new preclinical data showing that the antitumor activity of its lead candidate, Annamycin (naxtarubicin), in pancreatic cancer is at least partially mediated by CD8+ T cell cytotoxicity. The findings are being presented at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, held September 25–28, 2026 in San Diego, California. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: September 25, 2026 (Form 8‑K, Regulation FD disclosure).
• Drug: Annamycin (naxtarubicin) — lead drug candidate for pancreatic cancer.
• Scientific finding: Preclinical evidence that Annamycin’s antitumor effect is partially mediated by CD8+ T cell cytotoxicity.
• Presentation: Data presented at AACR Conference on Pancreatic Cancer, Sept 25–28, 2026; press release included as Exhibit 99.1.

Why It Matters
This is an early-stage (preclinical) disclosure about how Annamycin may exert antitumor effects, providing mechanistic data on immune involvement (CD8+ T cells). The disclosure was made publicly under Regulation FD and may be of interest to investors tracking Moleculin’s pipeline and scientific progress. Note this is preclinical data — not clinical trial results — and the filing does not report new financials, regulatory approvals, or clinical efficacy in humans.